Yıl: 2020 Cilt: 42 Sayı: 1 Sayfa Aralığı: 60 - 65 Metin Dili: İngilizce DOI: 10.14744/etd.2019.26986 İndeks Tarihi: 26-11-2020

Assessment of Post-transplantation Liver Function Tests in Patients Undergoing Allogeneic Stem Cell Transplantation

Öz:
Objective: Allogeneic hematopoietic stem cell transplantation is a treatment with a considerable rate of complete cure inhematological disorders. Hepatic complications are common causes of morbidity and mortality affecting the survival afterstem cell transplantation. This study was conducted to identify risk factors for hepatic dysfunction and related potential factorsaffecting the survival in patients undergoing allogeneic hematopoietic stem cell transplantation.Materials and Methods: We retrospectively evaluated the data from 300 allogeneic hematopoietic stem cell transplantationrecipients between March 2004 and May 2014 in the Erciyes University Hematology and Bone Marrow TransplantationCenter, Turkey. The study included 300 patients and their serial monitorization of the liver function tests, examined beforeand after transplantation.Results: The transplantation in 30 patients was performed from haploidentical donors and in 13 patients from unrelateddonors. We identified the liver function abnormalities in 71.7% of patients in the post-transplantation period. The mostcommon causes were graft-versus-host disease (43.6%), drug toxicity (24.7%), and sepsis (13.9%). Post-transplantation liverabnormalities were more common in patients with acute leukemia (p=0.02), iron overload (p<0.001), and in those who alsohad transaminitis in the pretransplantation period (p<0.001). Relapsed underlying disease (p<0.001), iron overload, anda bilirubin level >2 mg/dL in association with hepatic dysfunction during the post-transplantation period were identified asmajor factors influencing mortality following transplantation (p<0.001).Conclusion: We concluded that liver function abnormalities are frequent in the hematopoietic stem cell transplantationprocess. For a successful management, it is important to monitor the liver function and to identify additional risk factorsbefore and after transplantation.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Armitage JO. Bone marrow transplantation. N Engl J Med 1994; 330(12): 827–38.
  • 2. Eapen M, Logan BR, Appelbaum FR, Antin JH, Anasetti C, Couriel DR, et al. Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancy. Biol Blood Marrow Transplant 2015; 21(1): 55–9.
  • 3. Armenian SH, Sun CL, Francisco L, Baker KS, Weisdorf DJ, Forman SJ, et al. Health behaviors and cancer screening practices in long-term survivors of hematopoietic cell transplantation (HCT): a report from the BMT Survivor Study. Bone Marrow Transplant 2012; 47(2): 283–90.
  • 4. Ozdoğan O, Ratip S, Ahdab YA, Dane F, Ahdab HA, Imeryüz N, et al. Causes and risk factors for liver injury following bone marrow transplantation. J Clin Gastroenterol 2003; 36(5): 421–6.
  • 5. Pratt DS, Kaplan MM. Evaluation of liver function. In: Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J, editors. Harrison’s Principles of Internal Medicine. 18th Edition. USA: McGraw-Hill; 2012. pp. 302.
  • 6. Kim BK, Chung KW, Sun HS, Suh JG, Min WS, Kang CS, et al. Liver disease during the first post-transplant year in bone marrow transplantation recipients: retrospective study. Bone Marrow Transplant 2000; 26(2): 193–7.
  • 7. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11(12): 945–56.
  • 8. Akyol G, Kaynar L, Çetin M. New way in cancer therapy: PD-1 Inhibitors and hematologic diseases. Erciyes Med J 2019; 41(1): 12–7.
  • 9. Peker D. Navigating through mutations in Acute Myeloid Leukemia. What do we know and what do we do with it? Erciyes Med J 2018; 40(4): 183–7.
  • 10. Carreras E, Bertz H, Arcese W, Vernant JP, Tom ás JF, Hagglund H, et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 1998;92(10): 3599–604.
  • 11. Jordan K, Christensen IJ, J ørgensen MH, Heilmann C, Sengel øv H, Müller KG. Prognostic significance of liver parameters at 1-year followup in children and adults undergoing myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 2015; 50(6): 876–7.
  • 12. Kuru U, Senli S, Türel L, Kuru N, Başkent A, Ulucakli O. Age-specific seroprevalence of hepatitis B virus infection. Turk J Pediatr 1995; 37(4): 331–8.
  • 13. Thomas DL, Mahley RW, Badur S, Palaoglu E, Quinn TC. The epidemiology of hepatitis C in Turkey. Infection 1994; 22(6): 411–4.
  • 14. Yoo JJ, Cho EJ, Cho YY, Lee M, Lee DH, Cho Y, et al. Efficacy of antiviral prophylaxis in HBsAg-negative, anti-HBc positive patients undergoing hematopoietic stem cell transplantation. Liver Int 2015; 35(12): 2530–6.
  • 15. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al; Center for International Blood and Marrow Research; National Marrow Donor program; European Blood and MarrowTransplant Group; American Society of Blood and Marrow Transplantation; Canadian Blood and Marrow Transplant Group; Infectious Diseases Society of America; Society for Healthcare Epidemiology, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15(10): 1143–238.
  • 16. Arai S, Arora M, Wang T, Spellman SR, He W, Couriel DR, et al; Graftvs-Host Disease Working Committee of the CIBMTR. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant 2015; 21(2): 266–74.
  • 17. Boyiadzis M, Arora M, Klein JP, Hassebroek A, Hemmer M, UrbanoIspizua A, et al. Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia. Clin Cancer Res 2015; 21(9): 2020–8.
  • 18. Weisdorf D, Zhang MJ, Arora M, Horowitz MM, Rizzo JD, Eapen M. Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning. Biol Blood Marrow Transplant 2012; 18(11): 1727–33.
  • 19. Shulman HM, Hinterberger W. Hepatic veno-occlusive disease--liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant 1992; 10(3): 197–214.
  • 20. Jordan K, Pontoppidan P, Uhlving HH, Kielsen K, Burrin DG, Weischendorff S, et al. Gastrointestinal Toxicity, Systemic Inflammation, and Liver Biochemistry in Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2017; 23(7): 1170–6.
  • 21. Parimon T, Au DH, Martin PJ, Chien JW. A risk score for mortality after allogeneic hematopoietic cell transplantation. Ann Intern Med 2006; 144(6): 407–14.
  • 22. Goldberg SL, Klumpp TR, Magdalinski AJ, Mangan KF. Value of the pretransplant evaluation in predicting toxic day-100 mortality among blood stem-cell and bone marrow transplant recipients. J Clin Oncol 1998; 16(12): 3796-802.
  • 23. Barba P, Pi ñana JL, Fern ández-Avil és F, Perez-Sim ón JA, Martino R, López-Guerrero E, et al. Pretransplantation liver function impacts on the outcome of allogeneic hematopoietic stem cell transplantation: a study of 455 patients. Biol Blood Marrow Transplant 2011; 17(11): 1653–61.
  • 24. Morado M, Ojeda E, Garcia-Bustos J, Aguado MJ, Arrieta R, Quevedo E, et al. BMT: Serum Ferritin as Risk Factor for Veno-occlusive Disease of the Liver. Prospective Cohort Study. Hematology 2000; 4(6): 505–12.
  • 25. Sivgin S, Baldane S, Kaynar L, Kurnaz F, Pala C, Ozturk A, et al. Pretransplant serum ferritin level may be a predictive marker for outcomes in patients having undergone allogeneic hematopoietic stem cell transplantation. Neoplasma 2012; 59(2): 183–90.
  • 26. Armand P. Hyperferritinemia in stem cell transplantation. Biol Blood Marrow Transplant 2013; 19(3): 336–7.
  • 27. Sivgin S, Eser B. The management of iron overload in allogeneic hematopoietic stem cell transplant (alloHSCT) recipients: where do we stand? Ann Hematol 2013; 92(5): 577–86.
  • 28. Şahin C, Kaynar L , Kurnaz F, Pala C, Sivgin S, Eser B, et al. Factors that affect survival in patients with allogeneic hematopoetic stem cell transplantation. Erciyes Med J 2012; 34(4): 178–83.
APA kızıltepe m, Yildizhan E, ÜNAL A, ÇETİN M, Eser B, Kaynar L (2020). Assessment of Post-transplantation Liver Function Tests in Patients Undergoing Allogeneic Stem Cell Transplantation. , 60 - 65. 10.14744/etd.2019.26986
Chicago kızıltepe melih,Yildizhan Esra,ÜNAL Ali Tamer,ÇETİN Mustafa Alp,Eser Bülent,Kaynar Leylagul Assessment of Post-transplantation Liver Function Tests in Patients Undergoing Allogeneic Stem Cell Transplantation. (2020): 60 - 65. 10.14744/etd.2019.26986
MLA kızıltepe melih,Yildizhan Esra,ÜNAL Ali Tamer,ÇETİN Mustafa Alp,Eser Bülent,Kaynar Leylagul Assessment of Post-transplantation Liver Function Tests in Patients Undergoing Allogeneic Stem Cell Transplantation. , 2020, ss.60 - 65. 10.14744/etd.2019.26986
AMA kızıltepe m,Yildizhan E,ÜNAL A,ÇETİN M,Eser B,Kaynar L Assessment of Post-transplantation Liver Function Tests in Patients Undergoing Allogeneic Stem Cell Transplantation. . 2020; 60 - 65. 10.14744/etd.2019.26986
Vancouver kızıltepe m,Yildizhan E,ÜNAL A,ÇETİN M,Eser B,Kaynar L Assessment of Post-transplantation Liver Function Tests in Patients Undergoing Allogeneic Stem Cell Transplantation. . 2020; 60 - 65. 10.14744/etd.2019.26986
IEEE kızıltepe m,Yildizhan E,ÜNAL A,ÇETİN M,Eser B,Kaynar L "Assessment of Post-transplantation Liver Function Tests in Patients Undergoing Allogeneic Stem Cell Transplantation." , ss.60 - 65, 2020. 10.14744/etd.2019.26986
ISNAD kızıltepe, melih vd. "Assessment of Post-transplantation Liver Function Tests in Patients Undergoing Allogeneic Stem Cell Transplantation". (2020), 60-65. https://doi.org/10.14744/etd.2019.26986
APA kızıltepe m, Yildizhan E, ÜNAL A, ÇETİN M, Eser B, Kaynar L (2020). Assessment of Post-transplantation Liver Function Tests in Patients Undergoing Allogeneic Stem Cell Transplantation. Erciyes Medical Journal, 42(1), 60 - 65. 10.14744/etd.2019.26986
Chicago kızıltepe melih,Yildizhan Esra,ÜNAL Ali Tamer,ÇETİN Mustafa Alp,Eser Bülent,Kaynar Leylagul Assessment of Post-transplantation Liver Function Tests in Patients Undergoing Allogeneic Stem Cell Transplantation. Erciyes Medical Journal 42, no.1 (2020): 60 - 65. 10.14744/etd.2019.26986
MLA kızıltepe melih,Yildizhan Esra,ÜNAL Ali Tamer,ÇETİN Mustafa Alp,Eser Bülent,Kaynar Leylagul Assessment of Post-transplantation Liver Function Tests in Patients Undergoing Allogeneic Stem Cell Transplantation. Erciyes Medical Journal, vol.42, no.1, 2020, ss.60 - 65. 10.14744/etd.2019.26986
AMA kızıltepe m,Yildizhan E,ÜNAL A,ÇETİN M,Eser B,Kaynar L Assessment of Post-transplantation Liver Function Tests in Patients Undergoing Allogeneic Stem Cell Transplantation. Erciyes Medical Journal. 2020; 42(1): 60 - 65. 10.14744/etd.2019.26986
Vancouver kızıltepe m,Yildizhan E,ÜNAL A,ÇETİN M,Eser B,Kaynar L Assessment of Post-transplantation Liver Function Tests in Patients Undergoing Allogeneic Stem Cell Transplantation. Erciyes Medical Journal. 2020; 42(1): 60 - 65. 10.14744/etd.2019.26986
IEEE kızıltepe m,Yildizhan E,ÜNAL A,ÇETİN M,Eser B,Kaynar L "Assessment of Post-transplantation Liver Function Tests in Patients Undergoing Allogeneic Stem Cell Transplantation." Erciyes Medical Journal, 42, ss.60 - 65, 2020. 10.14744/etd.2019.26986
ISNAD kızıltepe, melih vd. "Assessment of Post-transplantation Liver Function Tests in Patients Undergoing Allogeneic Stem Cell Transplantation". Erciyes Medical Journal 42/1 (2020), 60-65. https://doi.org/10.14744/etd.2019.26986